| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Phase II trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fu-Qiang Yang, Gui-Rong Rao, Gui-Qiang Wang, Yue-Qi Li, Yao Xie, Zhan-Qing Zhang, Cun-Liang Deng, Qing Mao, Jun Li, Wei Zhao, Mao-Rong Wang, Tao Han, Shi-Jun Chen, Chen Pan, De-Ming Tan, Jia Shang, Ming-Xiang Zhang, Yue-Xin Zhang, Ji-Ming Yang and Guang-Ming Chen |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Yigan Biological Products Co., Ltd. of Guangzhou Pharmaceutical Holdings Ltd. (GPC, Guangzhou, China) |
|
| Guangdong Provincial Sci. & Tech. Project, No. 2012A080204009; Guangdong Provincial Natural Science Fun |
2014A030313770 |
| Guangdong Provincial Public Benefit Foundation |
2015A010107011 |
| National Key Program Grant for Management of AIDS and Viral Hepatitis in China 11th 5-Year Plan, |
2008ZX10002-003 |
|
| Corresponding Author |
Guang-Ming Chen, MD, Liver Disease Research Center, 458th Hospital of PLA, No. 801 Dongfeng E. Road, Guangzhou 510062, Guangdong Province, China. chgm0616@sina.com |
| Key Words |
Chronic hepatitis B; DNA vaccine; In vivo electroporation; Lamivudine-resistant mutants; Randomized placebo-controlled trial |
| Core Tip |
The study aimed to assess the efficacy and safety of in vivo electroporation-mediated dual-plasmid hepatitis B virus (HBV) DNA vaccine vs placebo for sequential combination therapy with lamivudine (LAM) in patients with chronic hepatitis B. The results indicated that the primary endpoint was not achieved using the HBV DNA vaccine. The HBV DNA vaccine might only be beneficial in subjects that have achieved initial virological response under LAM chemotherapy. |
| Publish Date |
2017-01-12 13:49 |
| Citation |
Yang FQ, Rao GR, Wang GQ, Li YQ, Xie Y, Zhang ZQ, Deng CL, Mao Q, Li J, Zhao W, Wang MR, Han T, Chen SJ, Pan C, Tan DM, Shang J, Zhang MX, Zhang YX, Yang JM, Chen GM. Phase Ⅱb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy. World J Gastroenterol 2017; 23(2): 306-317 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i2/306.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i2.306 |
